Sayed Goda

Sayed K Goda, a biochemistry and drug discovery professor, has a robust academic background. He earned a BSc in Chemistry and an MSc in organic chemistry from Cairo University, Egypt. He then pursued a PhD in Biochemistry from the University of Southampton, UK. Recognising the pivotal role of technology management in his field, he obtained an MBA in technology management from the Open University, UK, in 2000. His diverse educational background equips him with a unique perspective and a broad range of skills, making him a valuable asset in the field of biochemistry and drug discovery.

After completing his PhD, Sayed embarked on a leadership journey at the Porton Down establishment in Salisbury, UK, where he served for fourteen years as a senior scientist and a team leader. During that time, he led commercial and medically sensitive research. He employed protein engineering to produce novel commercially and medically important proteins. 

In 2002, Sayed's academic prowess and leadership skills led him to a professor position at Cairo University, Egypt. His tenure was marked by transformative contributions, notably the establishment of a new BSc Biotechnology program. He also supervised many successful MSc and PhD degrees.

In 2006, Dr. Goda accepted a professor position at Qatar University, Qatar, where he taught many major courses in biochemistry and biotechnology and successfully obtained many research grants.

In 2012, Sayed's expertise and reputation led him to a senior scientist and Professor position at the Antidoping laboratory in Qatar. He led research in various fields and established a protein engineering laboratory here. His exceptional ability to secure research funds, totalling over two million, for cancer-targeting drug discovery projects. His collaboration with Groningen University, Netherlands, resulted in the successful completion of four Ph. Ds and numerous publications, further solidifying his status as a prolific researcher.

Sayed has years of commercial and medical research experience in a conventional research institute in the UK.

He is also a regular reviewer for many high-impact journals, and he is currently a guest editor for Cancers.